NICE TA Adherence Check List September 2013
NICE TA Adherence Check list September 2013
Drug / Indication / NICE / Approval / Release Date / Formulary reviewOcriplasmin / Vitreomacular Traction / TA297 / Approved / 23/10/2013 / Yes
Aflibercept ( Eylea) / Wet-age related Macular degeneration / TA294 / Approved / 24/07/2013 / Yes
Eltrombopag / Idiopathic thrombocytopenia purpura / TA293 / Approved / 24/07/2013 / Yes
Aripiprazole (oral) / Bipolar Disorder (children 13yrs & over) / TA292 / Approved / 24/07/2013 / Yes
Mirabegron / Overactive Bladder / TA290 / Approved / 26/06/2013 / Yes
Dapagliflozin Combination thearpy / Type2 diabetes / TA288 / Approved / 26/06/2013 / Yes
Rivaroxaban / Pulmonary embolism & preventing recurrent venous thromboembolism / TA287 / Approved / 26/06/2013 / Yes
Ranibizumab / visual impairment caused by macular oedema secondary to retinal veil occlusion / TA283 / Approved / 22/05/2013 / Yes
Kyphoplasty / Vertebral Fractures / TA279 / Approved / 25/04/2013 / Yes
Pirfenidone / Idiopathic pulmonary fibrosis / TA282 / Approved / 24/04/2013 / Yes
Abatacept / RA (first TNF) / TA280 / Approved / 24/04/2013 / Yes
Vertebroplasty / Vertebral Fractures / TA279 / Approved / 24/04/2013 / Yes
Omalizumab / Asthma - over 12yo & adults / TA278 / Approved / 24/04/2013 / Yes
Omalizumab / Asthma - 6-11yo / TA278 / Approved / 24/04/2013 / Yes
Colistimethate Sodium / Cystic Fibrosis (pseudomonas lung infection) / TA276 / Approved / 27/03/2013 / Yes
Tobramycin / Cystic Fibrosis (pseudomonas lung infection) / TA276 / Approved / 27/03/2013 / Yes
Ranibizumab / Diabetic macular oedema / TA274 / Approved / 27/02/2013 / Yes
Apixaban / Stroke & Systemic embolism / TA275 / Approved / 27/02/2013 / Yes
Verumafenib / Locally Adv. Or metastatic BRAF V600 mutation-positive unresectable metastatic / TA269 / Approved / 12/12/2012 / Yes
Ipilimumab / Metastatic melanoma / TA268 / Approved / 12/12/2012 / Yes
Ivabradine / Heart Failure II - IV / TA267 / Approved / 28/11/2012 / Yes
Mannitol / Cystic Fibrosis / TA266 / Approved / 28/11/2012 / Yes
Botulinum toxin A / Chronic migraine / TA260 / Approved / 27/11/2012 / Yes
Denosumab / Bone Metastases for solid tumours / TA265 / Approved / 24/10/2012 / Yes
Alteplase / Acute ischaemic stoke / TA264 / Approved / 26/09/2012 / Yes
Rivaroxaban / deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism / TA261 / Approved / 25/07/2012 / Yes
Abiraterone (Zytiga) / Metastatic Castration resistant Prostate Ca / TA259 / Approved / 27/06/2012 / Yes
Erlotinib / NSCLC with EGFR activating mutations / TA258 / Approved / 27/06/2012 / Yes
Rivaroxaban / Stroke prevention in AF / TA256 / Approved / 23/05/2012 / Yes
Bocepravir / Genotype 1 chronic Hepatitis C / TA253 / Approved / 25/04/2012 / Yes
Telaprevir / Genotype 1 chronic Hepatitis C / TA252 / Approved / 25/04/2012 / Yes
Fingolimod / highly active relapsing–remitting multiple sclerosis (In Adults) / TA254 / Approved / 25/04/2012 / Yes
Dabigatranetexilate / Stroke prevention in AF / TA249 / Approved / 15/03/2012 / Yes
Exenatide LAR / Type 2 diabetes / TA248 / Approved / 22/02/2012 / Yes
Pharmalgen® / Hypersensitivity to bee & wasp venom / TA246 / Approved / 22/02/2012 / Yes
Tocilizumab / Rheumatoid arthritis / TA247 / Approved / 22/02/2012 / Yes
Apixaban / Prevention of VT after total Hip or Knee replacement in Adults / TA245 / Approved / 25/01/2012 / Yes
Rituximab / 1st line Treatment of Follicular Lymphoma stages III - IV / TA243 / Approved / 25/01/2012 / Yes
Roflumilast / COPD / TA244 / Approved / 25/01/2012 / Yes
Cyclophosphamide / Follicular lymphoma / TA243 / Approved / 25/01/2012 / Yes
Nilotinib / CML dasatinib, nilotinib, imatinib (intolerant, resistant) / TA241 / Approved / 13/01/2012 / Yes
Tocilizumab / Juvenile Idiopathic systemic arthritis / TA238 / Approved / 14/12/2011 / Yes
Ticagrelor / ACS / TA236 / Approved / 26/10/2011 / Yes
Mifamurtide / Osteosarcoma / TA235 / Approved / 26/10/2011 / Yes
Golimumab / Ankylosing spondylitis / TA233 / Approved / 24/08/2011 / Yes
Retigabine / Partial onset seizures / TA232 / Approved / 27/07/2011 / Yes
Bivalirudin / STEMI undergoing primary PCI / TA230 / Approved / 27/07/2011 / Yes
Dexamethasone implant (Ozurdex) / Macular oedema associated with retinal vein occlusion / TA229 / Approved / 27/07/2011 / Yes
Bortezomib / Multiple Myeloma (1st line) / TA228 / Approved / 27/07/2011 / Yes
Thalidomide / Mulitple myeloma (1st line) / TA228 / Approved / 27/07/2011 / Yes
Rituximab / Follicular NHL (maintenance) / TA226 / Approved / 22/06/2011 / Yes
Golimumab / Rheumatoid arthritis (2nd line ) / TA225 / Approved / 22/06/2011 / Yes
Naftidrofuryl oxalate / Intermiittent claudication associated with peripheral vasular disease / TA223 / Approved / 25/05/2011 / Yes
Romiplostim / Idiopathic thrombocytopenia purpura / TA221 / Approved / 27/04/2011 / Yes
Golimumab / Psoriatic arthritis / TA220 / Approved / 27/04/2011 / Yes
Rivastigmine / Alzheimer's disease / TA217 / Approved / 23/03/2011 / Yes
Rivastigmine (patch) / Alzheimer's disease / TA217 / Approved / 23/03/2011 / Yes
Donepezil / Alzheimer's disease / TA217 / Approved / 23/03/2011 / Yes
Galantamine / Alzheimer's disease / TA217 / Approved / 23/03/2011 / Yes
Azacitidine / Myelodysplastic syndrome / TA218 / Approved / 23/03/2011 / Yes
Memantine / Alzheimer's disease / TA217 / Approved / 23/03/2011 / Yes
Bendamustine / CLL (1st line) / TA216 / Approved / 23/02/2011 / Yes
Pazopanib / Metastatic renal cell Ca (1st line) / TA215 / Approved / 23/02/2011 / Yes
Aripiprazole (oral) / Schizophrenia (15-17yo) / TA213 / Approved / 26/01/2011 / Yes
Raloxifene / Secondary prevention of osteoporosis / TA161 / Approved / 26/01/2011 / Yes
Teriparatide / Osteoporosis / TA161 / Approved / 26/01/2011 / Yes
Alendronate / Secondary prevention / TA161 / Approved / 26/01/2011 / Yes
Etidronate / Secondary prevention / TA161 / Approved / 26/01/2011 / Yes
Risedronate / Secondary prevention / TA161 / Approved / 26/01/2011 / Yes
Strontium ranelate / Secondary prevention / TA161 / Approved / 26/01/2011 / Yes
Alendronate / Primary prevention / TA160 / Approved / 26/01/2011 / Yes
Etidronate / Primary prevention / TA160 / Approved / 26/01/2011 / Yes
Risedronate / Primary prevention / TA160 / Approved / 26/01/2011 / Yes
Strontium ranelate / Primary prevention / TA160 / Approved / 26/01/2011 / Yes
Prucalopride / Refractory constipation in women / TA211 / Approved / 15/12/2010 / Yes
Clopidogrel / Occlusive vascular events / TA210 / Approved / 15/12/2010 / Yes
Dipyridamole (MR) / Occlusive vascular events / TA210 / Approved / 15/12/2010 / Yes
Imatinib / Unresectable/metastatic GIST / TA86 / Approved / 24/11/2010 / Yes
Imatinib / Unresectable/metastatic GIST / TA209 / Approved / 24/11/2010 / Yes
Denosumab / Post-menopausal osteoporosis / TA204 / Approved / 27/10/2010 / Yes
Liraglutide / Type 2 diabetes / TA203 / Approved / 27/10/2010 / Yes
Adalimumab / Psoriatic arthritis / TA199 / Approved / 25/08/2010 / Yes
Etanercept / Psoriatic arthritis / TA199 / Approved / 25/08/2010 / Yes
Infliximab / Psoriatic arthritis / TA199 / Approved / 25/08/2010 / Yes
Dronedarone / AF / TA197 / Approved / 25/08/2010 / Yes
Abatacept / RA (after failure of TNF) / TA195 / Approved / 25/08/2010 / Yes
Adalimumab / RA (after failure of TNF) / TA195 / Approved / 25/08/2010 / Yes
Etanercept / RA (after failure of TNF) / TA195 / Approved / 25/08/2010 / Yes
Infliximab / RA (after failure of TNF) / TA195 / Approved / 25/08/2010 / Yes
Rituximab / RA (after failure of TNF) / TA195 / Approved / 25/08/2010 / Yes
Capecitabine / Advanced gastric Ca / TA191 / Approved / 28/07/2010 / Yes
Gefitinib / Locally-advanced or metastatic NSCLC (1st line) / TA192 / Approved / 28/07/2010 / Yes
Gefitinib / Locally-advanced or metastatic NSCLC (1st line) / TA192 / Approved / 28/07/2010 / Yes
Rituximab in combination with fludarabine & cyclophosphamide / CLL (relapsed or refractory) / TA193 / Approved / 28/07/2010 / Yes
Pemetrexed / NSCLC (maintenance) / TA190 / Approved / 23/06/2010 / Yes
Somatropin / Growth failure in children / TA188 / Approved / 26/05/2010 / Yes
Adalimumab / Crohn's disease / TA187 / Approved / 19/05/2010 / Yes
Infliximab / Crohn's disease / TA187 / Approved / 19/05/2010 / Yes
Certolizumabpegol / Rheumatoid arthritis / TA186 / Approved / 24/02/2010 / Yes
Trabectedin / Advanced soft tissue sarcoma / TA185 / Approved / 24/02/2010 / Yes
Topotecan (oral) / Relapsed SCLC / TA184 / Approved / 25/11/2009 / Yes
Cisplatin (in combination) / Cervical Ca / TA183 / Approved / 28/10/2009 / Yes
Topotecan / Cervical Ca / TA183 / Approved / 28/10/2009 / Yes
Prasugrel / ACS / TA182 / Approved / 28/10/2009 / Yes
Pemetrexed / NSCLC (1st line) / TA181 / Approved / 23/09/2009 / Yes
Ustekinumab / Psoriasis / TA180 / Approved / 23/09/2009 / Yes
Sunitinib / GIST / TA179 / Approved / 23/09/2009 / Yes
Alitretinoin / Chronic hand eczema / TA177 / Approved / 26/08/2009 / Yes
Cetuximab / Metastatic colorectal Ca (1st line) / TA176 / Approved / 26/08/2009 / Yes
Fluorouracil / Colorectal Ca (first line) / TA176 / Approved / 26/08/2009 / Yes
Tenofovirdisoproxil / Hepatitis B / TA173 / Approved / 22/07/2009 / Yes
Cyclophosphamide / CLL / TA174 / Approved / 22/07/2009 / Yes
Fludarabine phosphate / CLL / TA174 / Approved / 22/07/2009 / Yes
Rituximab / CLL / TA174 / Approved / 22/07/2009 / Yes
Lenalidomide / Mulitple myeloma / TA171 / Approved / 18/06/2009 / Yes
Rivaroxaban / VTE prophylaxis (post hip or knee replacement) / TA170 / Approved / 22/04/2009 / Yes
Sunitinib / Renal cell Ca (1st line) / TA169 / Approved / 25/03/2009 / Yes
Oseltamivir / Treatment of influenza / TA168 / Approved / 25/02/2009 / Yes
Zanamivir / Treatment of influenza / TA168 / Approved / 25/02/2009 / Yes
Infliximab / UC (acute exacerbations) / TA163 / Approved / 17/12/2008 / Yes
Febuxostat / Hyperuricaemia / TA164 / Approved / 17/12/2008 / Yes
Strontium ranelate / Secondary prevention / TA162 / Approved / 26/11/2008 / Yes
Erlotinib / NSCLC - treatment / TA162 / Approved / 26/11/2008 / Yes
Oseltamivir / Prevention of influenza / TA158 / Approved / 24/09/2008 / Yes
Zanamivir / Prevention of influenza / TA158 / Approved / 24/09/2008 / Yes
Dabigatranetexilate / VTE prophylaxis (post hip or knee replacement) / TA157 / Approved / 24/09/2008 / Yes
Ranibizumab / AMD / TA155 / Approved / 27/08/2008 / Yes
Entecavir / Hepatitis B / TA153 / Approved / 27/08/2008 / Yes
CSII (adults & Children over 12 years & over) / Type 1 diabetes / TA151 / Approved / 23/07/2008 / Yes
Adalimumab / Psoriasis / TA146 / Approved / 25/06/2008 / Yes
Cetuximab / Head & neck Ca (locally advanced) / TA145 / Approved / 25/06/2008 / Yes
Adalimumab / Ankylosing spondylitis / TA143 / Approved / 28/05/2008 / Yes
Etanercept / Ankylosing spondylitis / TA143 / Approved / 28/05/2008 / Yes
Darbopoetin / Ca treatment-induced anaemia / TA142 / Approved / 28/05/2008 / Yes
Epoetinalfa, beta & delta / Ca treatment-induced anaemia / TA142 / Approved / 28/05/2008 / Yes
Rituximab / Follicular non-Hodgkin's lymphoma / TA137 / Approved / 27/02/2008 / Yes
Infliximab / Psoriasis / TA134 / Approved / 23/01/2008 / Yes
Pemetrexed / Mesothelioma / TA135 / Approved / 23/01/2008 / Yes
Ezetimibe / Hypercholesterolaemia / TA132 / approved / 28/11/2007 / Yes
Adalimumab / RA (first TNF) / TA130 / Approved / 24/10/2007 / Yes
Etanercept / RA (first TNF) / TA130 / Approved / 24/10/2007 / Yes
Infliximab / RA (first TNF) / TA130 / Approved / 24/10/2007 / Yes
Bortezomib / Relapsed Multiple myeloma / TA129 / Approved / 24/10/2007 / Yes
Natalizumab / Multiple sclerosis / TA127 / Approved / 22/08/2007 / Yes
Varenicline / Smoking Cessation / TA123 / Approved / 25/07/2007 / Yes
Carmustine (implant) / Glioma / TA121 / Approved / 27/06/2007 / Yes
Temozolomide / Glioma / TA121 / Approved / 27/06/2007 / Yes
Gemcitabine / Metastatic breast Ca / TA116 / Approved / 24/01/2007 / Yes
Paclitaxel / Metastatic breast Ca / TA116 / Approved / 24/01/2007 / Yes
Cinacalcet / Secondary hyperparathyroidism / TA117 / Approved / 24/01/2007 / Yes
Buprenorphine / Managing OpiodDependancy / TA114 / Approved / 01/01/2007 / Yes
Methadone / Managing OpiodDependancy / TA114 / Approved / 01/01/2007 / Yes
Naltrexone / Managing OpiodDependancy / TA114 / Approved / 01/01/2007 / Yes
Anastrozole / Breast Ca / TA112 / Approved / 22/11/2006 / Yes
Exemestane / Breast Ca / TA112 / Approved / 22/11/2006 / Yes
Letrozole / Breast Ca / TA112 / Approved / 22/11/2006 / Yes
Doxorubicin hydrochloride / Breast Ca / TA109 / Approved / 21/09/2006 / Yes
Cyclophosphamide / Early breast Ca / TA109 / Approved / 21/09/2006 / Yes
Docetaxel / Early breast Ca / TA109 / Approved / 21/09/2006 / Yes
Ribavirin / Hepatitis C (mild) / TA106 / Approved / 26/08/2006 / Yes
Peginterferonalfa / Hepatitis C (mild) / TA106 / Approved / 26/08/2006 / Yes
Trastuzumab / Early breast Ca / TA107 / Approved / 23/08/2006 / Yes
Etanercept / Psoriasis / TA103 / Approved / 26/07/2006 / Yes
Docetaxel / Prostate Ca / TA101 / Approved / 28/06/2006 / Yes
Basiliximab / Renal transplantation (adults) / TA99 / approved / 26/04/2006 / Yes
Capecitabine / Colon Ca / TA100 / Approved / 26/04/2006 / Yes
Fluorouracil / Colon Ca / TA100 / Approved / 26/04/2006 / Yes
Oxaliplatin / Colon Ca / TA100 / Approved / 26/04/2006 / Yes
Peginterferonalfa / Hepatitis B / TA96 / Approved / 22/02/2006 / Yes
Adefovirdipivoxil / Hepatitis B / TA96 / Approved / 22/02/2006 / Yes
Carboplatin / Ovarian Ca (advanced) / TA91 / Approved / 01/05/2005 / Yes
Cisplatin / Ovarian Ca (advanced) / TA91 / Approved / 01/05/2005 / Yes
Doxorubicin hydrochloride (peg.lipsomal) / Ovarian Ca / TA91 / Approved / 01/05/2005 / Yes
Paclitaxel / Ovarian Ca (advanced) / TA91 / Approved / 01/05/2005 / Yes
Topotecan / Ovarian Ca / TA91 / Approved / 01/05/2005 / Yes
Basiliximab / Renal transplantation (adolescents & children) / TA85 / approved / 22/09/2004 / Yes
Pimecrolimus / Eczema / TA82 / Approved / 01/08/2004 / Yes
Tacrolimus / Eczema / TA82 / Approved / 01/08/2004 / Yes
Clopidogrel / ACS / TA80 / Approved / 01/07/2004 / Yes
Zaleplon / Insomnia / TA77 / Approved / 01/04/2004 / Yes
Interferon alfa / Hepatitis C (moderate-severe) / TA75 / Approved / 01/01/2004 / Yes
Peginterferonalfa / Hepatitis C (moderate-severe) / TA75 / Approved / 01/01/2004 / Yes
Ribavirin / Hepatitis C (moderate-severe) / TA75 / Approved / 01/01/2004 / Yes
Imatinib / CML / TA70 / Approved / 01/10/2003 / Yes
Cyclophosphamide / Aggressive non-Hodgkin's lymphoma / TA65 / Approved / 01/09/2003 / Yes
Doxorubicin hydrochloride / Non-Hodgkin's lymphoma / TA65 / Approved / 01/09/2003 / Yes
Verteprofin / PDT of AMD / TA68 / Approved / 01/09/2003 / Yes
Rituximab / Aggressive non-Hodgkin's lymphoma / TA65 / Approved / 01/09/2003 / Yes
Somatropin / Growth hormone deficiency in adults / TA64 / Approved / 01/08/2003 / Yes
Capecitabine / Metastatic colorectal Ca / TA61 / Approved / 01/05/2003 / Yes
Tegafur with uracil / Metastatic colorectal Ca / TA61 / Approved / 01/05/2003 / Yes
Paclitaxel / Ovarian Ca / TA55 / Approved / 01/01/2003 / Yes
Insulin glargine / Type 1&2 diabetes / TA53 / Approved / 01/12/2002 / Yes
Alteplase / Acute MI / TA52 / Approved / 01/10/2002 / Yes
Reteplase / Acute MI / TA52 / Approved / 01/10/2002 / Yes
Streptokinase / Acute MI / TA52 / Approved / 01/10/2002 / Yes
Tenecteplase / Acute MI / TA52 / Approved / 01/10/2002 / Yes
Etanercept / Juvenile arthritis / TA35 / Approved / 01/03/2002 / Yes
Gemcitabine / Pancreatic Ca / TA25 / Approved / 01/05/2001 / Yes
Temozolomide / Brain cancer / TA23 / Approved / 01/04/2001 / Yes
Riluzole / MND / TA20 / Approved / 01/01/2001 / Yes
Drug / Indication / NICE / Approval / Release Date / Approved for Local Use
Crizotinib / Lung CA / TA296 / Not Approved / 25/09/2013 / No
Everolimus / Advanced breast Ca / TA295 / not approved / 28/08/2013 / No
Pegloticase / Servere debilitating chronic tophaceous gout / TA291 / Not Approved / 26/06/2013 / No
Ruxolitinib / Disease-related splenomegaly or symptoms in adults with myelofibrosis / TA289 / Not Approved / 26/06/2013 / No
Bevacizumab in combo with Gemcitabine & Carboplatin / 1st recurrence of platinum-sensitive advanced ovarian cancer / TA285 / Not Approved / 22/05/2013 / No
Bevacizumab in combo with Paclitaxel & Carboplatin / 1st line treatment of advanced ovarian cancer / TA284 / Not Approved / 22/05/2013 / No
Loxapine inhalation / Acute agitation & disturbed behaviours associated with schizophrenia & bipolar disorder / TA286 / Terminated Appraisal / 22/05/2013 / No
Canakinumab / CAPS / TA281 / Terminated Appraisal / 24/04/2013 / No
Methylnalrexone / opioid-induced bowel dysfunction in people with advanced illness receiving palliative care / TA277 / Terminated Appraisal / 27/03/2013 / No
Vinflunine / TCCU / TA272 / Not approved / 23/01/2013 / No
Fluocinolone implant / Diabetic macular oedema / TA271 / Not Approved / 23/01/2013 / No
Tadalafil / Benign Prostatic Hyperplasia / TA273 / Terminated / 23/01/2013 / No
Decitabine / AML / TA270 / Not approved / 12/12/2012 / No
Bevacizumab / Adv/Metastatic breast Ca 1st line / TA263 / Not approved / 22/08/2012 / No
Adalimumab / Moderate-severe UC (2nd line) / TA262 / Not Approved / 27/06/2012 / No
Lapatinib / HER2 +ve metastatic breast Ca / TA257 / Not approved / 27/06/2012 / No
Trastuzumab / HER2 +ve metastatic breast Ca / TA257 / Not approved / 27/06/2012 / No
Cabazitaxel / Metastatic prostate Ca / TA255 / Not approved / 11/05/2012 / No
Dasatinib / CML 1st line / TA251 / Not approved / 25/04/2012 / No
Eribulin / Locally advanced or metastatic breast cancer / TA250 / Not approved / 03/04/2012 / No
Bevacizumab / Metastatic colorectal Ca 2nd Line / TA242 / Not approved / 25/01/2012 / No
Cetuximab / Metastatic colorectal Ca (2nd line) / TA242 / Not approved / 25/01/2012 / No
Panitumumab / Metastatic colorectal Ca (2nd line) / TA242 / Not approved / 25/01/2012 / No
Dasatinib / CML dasatinib, nilotinib, imatinib (intolerant, resistant) / TA241 / not approved / 13/01/2012 / No
Imatinib / CML dasatinib, nilotinib, imatinib (intolerant, resistant) / TA241 / Not approved / 13/01/2012 / No
Fulvestrant / Breast Ca / TA239 / Not approved / 14/12/2011 / No
Panitumumab / Metastatic colorectal Ca (2nd line) / TA240 / Terminated / 14/12/2011 / No
Bendamustine / Indolent NHL / TA206 / Not approved / 27/10/2011 / No
Agomelatine / Depression / TA231 / Not approved / 27/07/2011 / No
Erlotinib / NSCLC - maintenance / TA227 / Not approved / 29/06/2011 / No
Golimumab / RA (methotrexate-naïve) / TA224 / Terminated / 22/06/2011 / No
Cilostazol / Intermiittent claudication associated with peripheral vasular disease / TA223 / Not approved / 25/05/2011 / No
Inositol nicotinate / Intermiittent claudication associated with peripheral vasular disease / TA223 / Not Approved / 25/05/2011 / No
Pentoxifylline / Intermiittent claudication associated with peripheral vasular disease / TA223 / Not approved / 25/05/2011 / No
Trabectedin / Relapsed ovarian Ca / TA222 / Not approved / 27/04/2011 / No
Everolimus / Advanced RCC (2nd line) / TA219 / Not approved / 19/04/2011 / No
Bevacizumab / Metastatic breast Ca / TA214 / Not approved / 23/02/2011 / No
Raloxifene / Primary prevention of osteoporosis / TA160 / Not approved / 26/01/2011 / No
Bevacizumab / Metastatic colorectal Ca / TA212 / Not approved / 15/12/2010 / No
Trastuzumab / HER2 +ve metastatic gastric Ca / TA208 / Not approved / 24/11/2010 / No
Ofatumumab / CLL / TA202 / Not approved / 27/10/2010 / No
Fesoterodine / Non-Hodgkin's lymphoma / TA206 / Not approved / 27/10/2010 / No
Imatinib / GIST (adjuvant) / TA196 / Not approved / 25/08/2010 / No
Sorafenib / Hepatocellular Ca / TA189 / Not approved / 26/05/2010 / No
Sorafenib / Renal cell Ca / TA178 / Not approved / 29/08/2009 / No
Sunitinib / Renal cell Ca (2nd line) / TA178 / Not approved / 29/08/2009 / No
Temsirolimus / Renal cell Ca / TA178 / Not approved / 29/08/2009 / No
Bevacizumab / Renal cell Ca / TA178 / Not approved / 29/08/2009 / No
Cetuximab / Head & neck Ca (recurrent or metastatic) / TA172 / Not approved / 24/06/2009 / No
Amantadine / Treatment of influenza / TA168 / Not approved / 25/02/2009 / No
Amantadine / Prevention of influenza / TA158 / Not approved / 24/09/2008 / No
Pegaptanib sodium / AMD / TA155 / Not Approved / 27/08/2008 / No
Telbivudine / Hepatitis B / TA154 / Not approved / 27/08/2008 / No
Carmustine (implant) / Glioblastomamultiforme / TA149 / Not approved / 25/06/2008 / No
Bevacizumab / NSCLC / TA148 / Not approved / 25/06/2008 / No
Infliximab / Ankylosing spondylitis / TA143 / Not Approved / 28/05/2008 / No
Infliximab / UC (sub-acute manifestations) / TA140 / Not Approved / 23/04/2008 / No
Pemetrexed / NSCLC (2nd line) / TA124 / Not approved / 22/08/2007 / No
Fludarabine phosphate / CLL / TA119 / Not approved / 28/02/2007 / No
Bevacizumab / Adv./metastatic colorectal Ca / TA118 / Not approved / 24/01/2007 / No
Cetuximab / Metastatic colorectal Ca (2nd line) / TA118 / Not approved / 24/01/2007 / No
Fluorouracil / Colorectal Ca (metastatic) / TA118 / Not approved / 24/01/2007 / No
Paclitaxel / Early breast Ca / TA108 / Not approved / 27/09/2006 / No
Efalizumab / Psoriasis / TA103 / Market Authorisation withdrawn / 26/07/2006 / No
Drotrecoginalfa / Sepsis / TA84 / terminated / No
Temsirolimus / Mantle cell lymphoma / TA207 / Terminated / No